NCM
YARW

Nantahala Capital Management’s Yarrow Bioscience YARW Stock Holding History

Nantahala Capital Management’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Hold
40,000
– – 0.04% 142
2026
Q1 		$1.2M Buy
40,000
+20,000
+100% +$583K 0.04% 140
2025
Q4 		$580K Buy
+20,000
New +$401K 0.02% 143

Other funds holding YARW

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Nantahala Capital Management's YARW Position: Q2 2026 in Review

Nantahala Capital Management held its Yarrow Bioscience (YARW) position steady in Q2 2026 at 40,000 shares worth $1.3M. The position accounts for 0.04% of the portfolio, ranked #142.

Nantahala Capital Management first reported a position in YARW in Q4 2025 and has held it in 3 quarters since. 40 funds tracked by Wall St. Rank hold YARW as of Q2 2026.

  • Nantahala Capital Management held 40,000 shares of Yarrow Bioscience worth $1.3M as of Q2 2026.
  • Nantahala Capital Management left its Yarrow Bioscience share count unchanged in Q2 2026.
  • Yarrow Bioscience made up 0.04% of Nantahala Capital Management's portfolio in Q2 2026, its #142 holding.
  • Nantahala Capital Management first reported a position in Yarrow Bioscience in Q4 2025 and has held it in 3 quarters since.
  • 40 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.